Get the Stockscreener App
9.30
0.64%
-0.06
After Hours:
9.30
Arcutis Biotherapeutics Inc stock is traded at $9.30, with a volume of 1.92M.
It is down -0.64% in the last 24 hours and down -14.52% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$9.36
Open:
$9.32
24h Volume:
1.92M
Relative Volume:
0.86
Market Cap:
$1.08B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-1.6787
EPS:
-5.54
Net Cash Flow:
$-247.49M
1W Performance:
-3.43%
1M Performance:
-14.52%
6M Performance:
-6.16%
1Y Performance:
+75.14%
1-Day Range:
$9.14
$9.74
1-Week Range:
$9.02
$10.04
52-Week Range:
$1.76
$13.17
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Perceptive Advisors LLC Buys 808,500 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations - Dermatology Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Profund Advisors LLC Sells 78,093 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics CFO sells shares worth over $110,000 By Investing.com - Investing.com Australia
Arcutis Biotherapeutics CFO sells shares worth over $110,000 By Investing.com - Investing.com Canada
Arcutis Biotherapeutics CFO sells shares worth over $110,000 - Investing.com
Arcutis Wants to Be A Go-To Treatment - San Fernando Valley Business Journal
Arcutis' supplemental application for Zoryve accepted by FDA - MSN
FDA sets review date for new psoriasis treatment By Investing.com - Investing.com Australia
Arcutis announces new pooled subgroup analysis results from INTEGUMENT-1 trial - TipRanks
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types - ForexTV.com
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types - StockTitan
Arcutis Biotherapeutics Inc [ARQT] Stock sold by Insider Welgus Howard G. for $0.11 million - Knox Daily
FDA accepts roflumilast's sNDA to treat scalp and body psoriasis in adolescents, adults - Contemporary Pediatrics
Rabiya Mateo sets the record straight on relationship with Jeric Gonzales - LionhearTV
FDA Accepts sNDA for Roflumilast Foam as Scalp, Body Psoriasis Treatment - MD Magazine
Ratio Examination: Arcus Biosciences Inc (RCUS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
FDA sets review date for new psoriasis treatment - Investing.com
FDA sets review date for new psoriasis treatment - Investing.com India
Arq Inc. CEO Robert E. Rasmus buys $131,250 in company stock - Investing.com
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over - StockTitan
Apriori Bio Appoints World-Class Vaccine, Immunology and Public Health Leaders to Board of Directors - PR Newswire
38,761 Shares in Arcus Biosciences, Inc. (NYSE:RCUS) Purchased by XTX Topco Ltd - Defense World
(ARQT) Trading Report - Stock Traders Daily
Ensign Peak Advisors Inc Reduces Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Assicurazioni Generali (OTCMKTS:ARZGY) Shares Up 0.1% - Defense World
Metric Deep Dive: Understanding Arcutis Biotherapeutics Inc (ARQT) Through its Ratios - The Dwinnex
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry - Simply Wall St
Brighton Jones LLC Takes Position in United Rentals, Inc. (NYSE:URI) - Defense World
American Century Companies Inc. Buys 190,754 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Aldi Australia set to bring back a popular $15 garden item - MSN
Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones - Seeking Alpha
Rabiya Mateo Speaks About Unfollowing, Breakup Issues w/ Jeric Gonzales - PhilNews
Rubric Capital Management LP Acquires 2,306,672 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
ZORYVE cream shows promise in atopic dermatitis treatment - Investing.com India
ZORYVE cream shows promise in atopic dermatitis treatment - Investing.com
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology - StockTitan
Arcutis Biotherapeutics Inc Inc. (ARQT) Price Performance Over the Years: A Comparative Study - The InvestChronicle
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.5% - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.3% - MarketBeat
Arcus Biosciences Inc (RCUS) looking to reclaim success with recent performance - SETE News
A closer look at Arcutis Biotherapeutics Inc (ARQT)’s stock price trends - US Post News
Quest Partners LLC Raises Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Griffin Dunne In Conversation With Amy Robinson Will Benefit The West Bank Cafe and Laurie Beechman Theatre - BroadwayWorld
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.8% - MarketBeat
Can you still get a good price for Arcus Biosciences Inc (RCUS) Shares at this point? - US Post News
Market Recap: Arcus Biosciences Inc (RCUS)’s Negative Momentum, Closing at 16.90 - The Dwinnex
Arcturus Therapeutics Holdings Inc (ARCT) expanding its growth trajectory ahead - SETE News
Here's Why Investors Should Invest in Arcturus Stock Now - Zacks Investment Research
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):